Post-earnings recap
Reported
Thu, May 9, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a larger-than-expected loss per share, which contributed to a 1.0% decline in stock price following the announcement. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. Management's cautious tone suggests they are aware of the challenges ahead.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.48 | N/A | -17.07% |
Overall, management expressed concern over recent performance but remains committed to long-term goals. They highlighted the importance of ongoing projects.
Management acknowledged the challenges faced during the quarter.
They emphasized the need for continued focus on product development.